June 14, 2023
Indies Pharma Jamaica Limited (INDIES) has advised that its ANDA (abbreviated new drug application) for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL), dated January 25, 2023, was submitted under section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) at the U.S. Food & Drug Administration (“FDA”). The Company has received an Agency’s letter titled ‘PARAGRAPH IV ACKNOWLEDGEMENT ANDA RECEIPT” dated February 28, 2023. INDIES has also advised that on June 13, 2023, it submitted the patent amendment and notified the FDS that the stipulated statutory 45-day period after receipt of notice letter has passed, and no challenge has been filed against the Company by the original patent holder of NDA (new drug application) N022161 noted on the records of the U.S. Food & Drug Administration (“FDA”).
Disclaimer:
Analyst Certification -The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.
Company Disclosure -The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may affect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.
